SB218078
SB218078 性质
| 熔点 | >340 °C |
|---|---|
| 密度 | 1.80±0.1 g/cm3(Predicted) |
| 储存条件 | Store at RT |
| 溶解度 | DMSO 中≤5mg/ml；二甲基甲酰胺中≤5mg/ml |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | 9.75±0.20(Predicted) |
| 颜色 | 浅黄至黄色 |
| InChI | 1S/C24H15N3O3/c28-23-19-17-11-5-1-3-7-13(11)26-15-9-10-16(30-15)27-14-8-4-2-6-12(14)18(22(27)21(17)26)20(19)24(29)25-23/h1-8,15-16H,9-10H2,(H,25,28,29) |
| InChIKey | OTPNDVKVEAIXTI-UHFFFAOYSA-N |
SB218078 用途与合成方法
|
Chk1 15 nM (IC 50 ) |
Cdc2 250 nM (IC 50 ) |
PKC 1000 nM (IC 50 ) |
Apoptosis
|
SB-218078 (2.5-5 μM; 18 hours; HeLa cells) treatment abrogates G2 cell cycle arrest caused by either γ-irradiation or a topoisomerase I Topotecan inhibition.
SB-218078 (500-625 μM; 96 hours; HeLa and HT-29 cells) treatment significantly increases the cytotoxicity of DNA damage .
Cell Cycle Analysis
| Cell Line: | HeLa cells |
| Concentration: | 2.5 μM, 5 μM |
| Incubation Time: | 18 hours |
| Result: | Abrogated G2 cell cycle arrest caused by γ-irradiation and topoisomerase I inhibition. |
Cell Cytotoxicity Assay
| Cell Line: | HeLa and HT-29 cells |
| Concentration: | 500 nM, 625 nM |
| Incubation Time: | 96 hours |
| Result: | Enhanced cytotoxicity of DNA damage. |
SB-218078 (5 mg/kg; intraperitoneal injection; for 16 hours; C57/Bl6 mice) treatment could promote a strong increase of γ-H2AX and apoptosis throughout the lymphoma, while having no effect on a healthy spleen in Myc-induced lymphomas mouse model.
| Animal Model: | C57/Bl6 mice injected with ARF -/- lymphomas |
| Dosage: | 5 mg/kg |
| Administration: | Intraperitoneal injection; for 16 hours |
| Result: | Promoted a strong increase of γ-H2AX and apoptosis throughout the lymphoma. |
SB218078 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-107407 | SB218078 | 135897-06-2 | 1 mg | 1380 |
| 2026-09-15 | HY-107407 | SB218078 | 135897-06-2 | 5 mg | 3450 |
